98%
921
2 minutes
20
Plasma cell-free DNA (cfDNA) is a noninvasive biomarker for cell death of all organs. Deciphering the tissue origin of cfDNA can reveal abnormal cell death because of diseases, which has great clinical potential in disease detection and monitoring. Despite the great promise, the sensitive and accurate quantification of tissue-derived cfDNA remains challenging to existing methods due to the limited characterization of tissue methylation and the reliance on unsupervised methods. To fully exploit the clinical potential of tissue-derived cfDNA, here we present one of the comprehensive and high-resolution methylation atlas based on 521 noncancer tissue samples spanning 29 major types of human tissues. We systematically identified fragment-level tissue-specific methylation patterns and extensively validated them in orthogonal datasets. Based on the rich tissue methylation atlas, we develop the supervised tissue deconvolution approach, a deep-learning-powered model, , for sensitive and accurate tissue deconvolution in cfDNA. On the benchmarking data, showed superior sensitivity and accuracy compared to the existing methods. We further demonstrated the clinical utilities of with two potential applications: aiding disease diagnosis and monitoring treatment side effects. The tissue-derived cfDNA fraction estimated from reflected the clinical outcomes of the patients. In summary, the tissue methylation atlas and enhanced the performance of tissue deconvolution in cfDNA, thus facilitating cfDNA-based disease detection and longitudinal treatment monitoring.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334733 | PMC |
http://dx.doi.org/10.1073/pnas.2305236120 | DOI Listing |
NPJ Precis Oncol
September 2025
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Breast cancer is a highly heterogeneous disease with diverse outcomes, and intra-tumoral heterogeneity plays a significant role in both diagnosis and treatment. Despite its importance, the spatial distribution of intra-tumoral heterogeneity is not fully elucidated. Spatial transcriptomics has emerged as a promising tool to study the molecular mechanisms behind many diseases.
View Article and Find Full Text PDFUnlabelled: Passive Acoustic Mapping (PAM) is rapidly emerging as a ubiquitous tool for real-time localization and monitoring of therapeutic ultrasound treatments involving cavitation in the context of safety or efficacy. The ability of PAM to spatially quantify and resolve cavitation activity offers a unique opportunity to correlate the energy of cavitation phenomena with locally observed bioeffects.
Objective: We aim to develop methods of measuring and reporting spatio-temporally varying cavitation energies that are energy-preserving, device-independent, and adequately normalized to the volume of tissue being affected by the reported cavitation activity.
Dev Biol
September 2025
Massachusetts Eye and Ear, Boston, MA; Department of Ophthalmology, Harvard Medical School, Boston, MA. Electronic address:
Tissue development is a complex spatiotemporal process with multiple interdependent components. Anatomical, histological, sequencing, and evolutional strategies can be used to profile and explain tissue development from different perspectives. The introduction of single-cell RNA sequencing (scRNAseq) methods and the computational tools allows to deconvolute developmental heterogeneity and draw a decomposed uniform map.
View Article and Find Full Text PDFNAR Genom Bioinform
September 2025
Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, 518005 Guangdong, China.
Single-cell RNA sequencing (scRNA-seq) has significantly deepened our understanding of cellular heterogeneity and cell type interactions, providing insights into how cell populations adapt to environmental variability. However, its lack of spatial context limits intercellular analysis. Similarly, existing spatial transcriptomics (ST) data often lack single-cell resolution, restricting cellular mapping.
View Article and Find Full Text PDFHum Reprod Open
August 2025
Biology of the Testis (BITE) Laboratory, Genetics, Reproduction and Development (GRAD) Research Group, Vrije Universiteit Brussel, Brussels, Belgium.
Study Question: Can testicular tissue from trans women (trans tissue) be used to create human testicular organoids?
Summary Answer: Testosterone-producing and cytotypic human testicular organoids with bicompartmental architecture can be successfully generated from trans tissue.
What Is Known Already: Testicular organoids are a promising tool for studying testicular function and the effects of toxicants. Immature testicular cells are currently the most efficient at forming organoids that closely recapitulate seminiferous tubule-like architecture and functions.